Edition:
United States

CytRx Corp (CYTR.OQ)

CYTR.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
291,262
52-wk High
$3.66
52-wk Low
$0.37

Latest Key Developments (Source: Significant Developments)

Cytrx Corp says files for mixed shelf offering of up to $200 mln- SEC filing
Thursday, 22 Dec 2016 02:17pm EST 

Cytrx Corp - :Cytrx Corp says files for mixed shelf offering of up to $200 million - SEC filing.  Full Article

Cytrx presents positive interim results from on-going clinical trial
Friday, 11 Nov 2016 09:00am EST 

Cytrx Corp : Cytrx says dose-limiting toxicities were not observed in either cohort, and no clinically significant cardiac toxicities were seen . Cytrx says there were nine treatment-related serious adverse events, and no treatment-related deaths .Cytrx presents positive interim results from on-going phase 1b/2 aldoxorubicin combination clinical trial at the 2016 ctos annual meeting.  Full Article

Cytrx reports loss per share of $0.27 for Q2 2016
Friday, 29 Jul 2016 09:00am EDT 

Cytrx Corp :Q2 loss per share $0.27.  Full Article

Cytrx Corp announces pricing of $20 mln public offering
Friday, 15 Jul 2016 07:30am EDT 

Cytrx Corp : Cytrx Corp announces pricing of $20 million public offering of common stock and warrants . Priced offering of an aggregate of approximately 28.6 million shares of common stock at a price to public of $0.70 per share .Investors will also receive warrants to purchase up to approximately 28.6 million shares with an exercise price of $0.70 per share.  Full Article

CytRx presents updated Aldoxorubicin trial results
Monday, 6 Jun 2016 09:00am EDT 

CytRx Corp : Cytrx Corp says clinical data presented at asco continues to support safety and activity of aldoxorubicin in multiple high unmet need tumor types .Cytrx presents updated aldoxorubicin clinical trial results at the 2016 american society of clinical oncology annual meeting.  Full Article

Cytrx Corp issued 1.6 mln shares for benefit of claimants of IN RE Cytrx securities litigation
Friday, 27 May 2016 12:35pm EDT 

: Cytrx Corp says on May 25, 2016, issued for benefit of claimants in matter of IN RE Cytrx Securities litigation total of 1.6 million shares of stock . Cytrx Corp says shares were issued pursuant to court's judgment and order granting final approval of previously announced settlement of matter . Cytrx Corp says for purposes of this settlement, the shares were valued at an aggregate of $4.5 million - SEC Filing Source - http://1.usa.gov/1U0Sgqg (Bengaluru Newsroom; +1 646 223 8780).  Full Article

CytRx reports Q1 loss per share $0.19
Wednesday, 11 May 2016 09:11am EDT 

CytRx Corp : CytRx reports first quarter 2016 financial results . Q1 loss per share $0.19 .Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Cytrx announces publication of positive global phase 2b clinical trial results for Soft Tissue Sarcoma in Peer-Reviewed JAMA Oncology
Monday, 21 Sep 2015 09:00am EDT 

Cytrx Corp:Says aldoxorubicin demonstrates significantly superior efficacy over doxorubicin.Patients treated with aldoxorubicin exhibited manageable adverse effects,had no unexpected events,did not show evidence of acute cardiotoxicity.Primary endpoint results found that subjects treated with aldoxorubicin demonstrated highly statistically significantly better clinical outcomes.  Full Article

CytRx Corp says closing of public offering of common stock
Friday, 24 Jul 2015 11:00am EDT 

CytRx Corp:Closing of its previously announced underwritten public offering.Gross proceeds from its sale of 10,465,000 shares of common stock at a public offering price of $2.75 per share.Intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and its drug discovery activities and for general corporate purposes.Jefferies LLC acted as the sole book-running manager for the offering.Oppenheimer & Co. Inc., Aegis Capital Corp., FBR Capital Markets & Co., and H.C. Wainwright & Co. acted as co-lead managers for the offering.  Full Article

CytRx Corp announces pricing of public offering of 9.1 million shares of common stock
Tuesday, 21 Jul 2015 08:45am EDT 

CytRx Corp:Announces pricing of public offering of 9.1 million shares of common stock.Says offering of 9.1 million common shares priced at $2.75 per share.  Full Article

More From Around the Web

BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx-Reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas